To assess the role of tau protein, beta-amyloid(1-42) and cystatin C in the diagnostics of Alzheimer dementia (AD) and other neurodegenerative diseases (ND) by comparing to the control groups (CG). The levels of tau protein, beta-amyloid(1-42) and cystatin C were assessed in the set of 69 patients (AD + ND, 33 males, 36 females, aged 22-90, mean 60.5 + 16.1 years), and in a control group of 69 subjects without the affection of the central nervous system (CGAD + CGND, 33 males, 36 females, aged 20-91, mean 60.5 + 16.0 years). Statistically significant increased tau protein levels (P = 0.0001) and index tau/beta-amyloid(1-42) levels (P = 0.0002) were shown in the group of AD patients, compared to the group of ND patients. One-way ANOVA analysis with Bonferonni post hoc test did not show any significant differences of the cystatin C values between any of the compared groups. ROC analysis showed at least one tie between the positive actual state group (AD) and the negative actual state group (ND) by CSF cystatin C and at least one tie between the positive actual state group and the negative actual state group by CSF tau protein. Our study confirmed previously reported results only in part. While tau protein seems to be quite a reliable marker of AD, the role of beta-amyloid(1-42) and cystatin C in AD diagnosis remains at least questionable.
- MeSH
- Alzheimerova nemoc diagnóza patofyziologie MeSH
- amyloidní beta-protein analýza MeSH
- biologické markery analýza MeSH
- cystatin C analýza MeSH
- degenerace nervu diagnóza patofyziologie MeSH
- dospělí MeSH
- financování organizované MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- peptidové fragmenty analýza MeSH
- prediktivní hodnota testů MeSH
- proteiny tau analýza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- upregulace fyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
OBJECTIVES: The aim of our work was to assess the role of tau protein, beta amyloid and cystatin C in diagnosis of Alzheimer dementia (AD) and other neurodegenerative diseases (NDs). METHODS: The levels of tau protein, beta amyloid and cystatin C were assessed in a set of 79 patients with ND (38 men and 41 women; aged 22-90 years; mean, 61.6 +/- 15.6 years) and in a control group of 79 subjects with a healthy central nervous system (38 men and 41 women; aged 20-91 years; mean, 61.5 +/- 15.1 years). RESULTS: When compared with the subjects in the control group, a statistically significant decrease in tau protein levels was found in patients with ND, an increase in tau protein levels in patients with AD and an increase in cystatin C cerebrospinal fluid/serum index in the ND + AD group. DISCUSSION: Our work only confirmed the previously reported results in part. Although tau protein seems to be a quite reliable marker of AD, the role of beta amyloid in AD diagnosis remains at the least questionable. In the case of cystatin C, our results would seem to confirm the views of certain authors that cystatin C will probably not become a new 'revolutionary' marker contributing to differential diagnostics.
- MeSH
- Alzheimerova nemoc diagnóza MeSH
- amyloidní beta-protein diagnostické užití MeSH
- biologické markery MeSH
- cystatin C diagnostické užití MeSH
- diferenciální diagnóza MeSH
- dospělí MeSH
- ELISA MeSH
- lidé středního věku MeSH
- lidé MeSH
- neparametrická statistika MeSH
- proteiny tau diagnostické užití MeSH
- referenční hodnoty MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
Závěrečná zpráva o řešení grantu Interní grantové agentury MZ ČR
127 l. : tab., grafy ; 30 cm
Projekt je zaměřen na ověření (vyvrácení) hypotézy o využití stanovení cystatinu C v likvoru ( séru) v diagnostice ( event. predikci rizika vzniku) neurodegenerativních chorob.; This project is covered on verification (or refutation) of hypothesis about application of the cystatin C delimitations in CSF (serum) for the diagnostic (alternatively the prediction for the liability of origin) of the neurodegenerative disease.
- MeSH
- Alzheimerova nemoc diagnóza MeSH
- amyloidní beta-protein MeSH
- biochemické jevy MeSH
- biologické markery MeSH
- cystatiny diagnostické užití fyziologie MeSH
- diagnóza MeSH
- neurodegenerativní nemoci diagnóza MeSH
- proteiny v mozkomíšním moku MeSH
- Konspekt
- Biochemie. Molekulární biologie. Biofyzika
- NLK Obory
- biochemie
- neurologie
- diagnostika
- NLK Publikační typ
- závěrečné zprávy o řešení grantu IGA MZ ČR
225 consecutive patients with different neurological diseases and 101 individuals as the control were examined between 2002-2004. Cystatin C, arginase-I, tau-protein and beta-amyloid were measured. Individuals with CNS inflammation had significantly lower Cystatin-C index (CSF/serum) values. There was no diagnostic significance of the Arginase-I assay in CSF was verified. The CSF tau-protein/beta-amyloid index was shown to be a sufficient efficacy for neurodegenerative disease diagnosis.
This paper presents a current view of the possible clinical uses of cystatin C determination. Cystatin C is an inhibitor of cysteine proteases, and relatively stable in the systemic circulation it is comparatively easily determined. Although in clinical practice it is known primarily as a relatively reliable and endogenous marker for glomerular filtration, lately cystatin C analysis has been discussed in connection with the diagnostics of a variety of diseases such as early atherosclerosis, Alzheimer's dementia, vascular aneurysms, hyperhomocysteinaemia and other neurodegenerative diseases.
- MeSH
- dospělí MeSH
- hořčík aplikace a dávkování terapeutické užití MeSH
- imobilizace MeSH
- ischemie mozku MeSH
- klinické laboratorní techniky statistika a číselné údaje MeSH
- koronární cévy patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- osteoporóza diagnóza etiologie terapie MeSH
- vápník aplikace a dávkování terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- srovnávací studie MeSH
